14:44 IST
NSE
Acquisition
Marksans Pharma Acquisition
Marksans Pharma Ltd has completed the acquisition of QliniQ B.V., obtaining 100% share capital. The transaction expands Marksans' presence in the Netherlands.
Marksans Pharma Ltd
- Share price
- ₹325.00
- Market cap
- ₹14,728 Cr
- Revenue (annual)
- ₹2,951 Cr
- Net profit (annual)
- ₹417.9 Cr
- P/E (TTM)
- 28.5×Sector 47.4×
- Promoter holding
- 43.87%+0.00% QoQ
- FII holding
- 17.47%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
All
Earnings Call 6Other Announcement 4Financial Results 3Acquisition 3Merger & Restructuring 2Board Meeting Date 2Annual General Meeting 2Results Update 1Promoter Selling (Off-Market) 1Employee Stock Options 1Dividend 1Credit Rating 1Business Update 1Board Meeting Outcome 1Annual Report 1
Time
3 announcements with these filters
00:34 IST
NSE
Acquisition
Marksans Pharma Acquisition Worth ₹82.98 Cr
Marksans Pharma acquired 100% of Netherlands-based QliniQ B.V. for ₹82.98 Crore. The deal strengthens its European distribution and marketing infrastructure for Indian-manufactured products.
- Value
- ₹82.98 Cr
- Execution
- Expected completion by June 15, 2026
08:57 IST
BSE
Acquisition
Marksans Pharma Acquisition Worth ₹71.25 Cr
Marksans Pharma is acquiring 100% of Netherlands-based QliniQ B.V. for ₹71.25 Crore. The deal strengthens Marksans' European distribution and forward-integration strategy.
- Value
- ₹71.25 Cr
- Execution
- Expected completion by June 15, 2026